Bayesian Capital Management’s CureVac CVAC Stock Holding History

Bayesian Capital Management’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-11,736	Closed	-$230K	–	840
2022 Q1	$230K	Buy	+11,736	New	+$234K	0.03%	608

Other funds holding CVAC

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

Bayesian Capital Management's CVAC Position: Q2 2022 in Review

Bayesian Capital Management sold out of CureVac (CVAC) in Q2 2022, closing a stake of 11,736 shares — an estimated $230K sold.

Bayesian Capital Management first reported a position in CVAC in Q1 2022 and held it in 1 quarter. The position peaked at $230K in Q1 2022. 88 funds tracked by Wall St. Rank hold CVAC as of Q2 2022.

Bayesian Capital Management reported no remaining CureVac position as of Q2 2022 after selling out during the quarter.
Bayesian Capital Management sold 11,736 CureVac shares in Q2 2022, an estimated $230K.
Bayesian Capital Management first reported a position in CureVac in Q1 2022 and held it in 1 quarter.
Bayesian Capital Management's CureVac position peaked at $230K in Q1 2022.
88 funds tracked by Wall St. Rank held CureVac as of Q2 2022.

Based on Bayesian Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.